Bot Chart, page-2855

The Board will seek that phase 3 meeting next year and considering their confidence, and their exasperation in the American results, you have to hope that their direction has been envisaged by decades of previous experience. I am sure not all of those 'TO MARKET' pharmaceuticals that were eventually approved all went as cruisy thru phase 1, 2 then 3 knock out. No way.

1503 works here and over there.
It works damn well.
It has bugger all side effects too.
It probably has few contraindications.
It is certainly novel, but Cassiopeia also has a new hormone antagonist that is novel.
We have just had released something called Acnarax or close to it combining two actives but you have to be careful of excessive sunlight due to the tretinoin in it.

1503 has such a huge potential, but yet to be shown outside of here. It's that simple.

But this is where I personally think and obviously adopt the BHP principle like you have. We've Bought, are Hoping and we Pray. To Allah, to God, to Joseph Smith, to Buddha.

Did you pick up on the comments by management saying that AD is an even bigger market? Sure there might be bravado attached but also added was the fact that the vehicle and active AD cream were manufactured ideally this time. Probably made in a state of the art facility in New York, under the NYSE. This was a prominent point made by Vinnie in his October statement.
There are a couple of hundred patients in the AD trial, again from 12 and up. This is a great admission of our safety profile. I would wonder whether there is a chance of seriously hitting a home run in the AD trial if you used three or four strengths of the CBD to give a better spread going into a hopeful phase 3?

I have no idea but just thinking laterally as that is what Dr Mark in sunny Queensland would do.

At this stage and with all of the initial clinical stuff going on pre phase 3, we have plenty of cash sitting around.

I am also considering other pins in our alley as much as books in our eventual library.